Success Metrics

Clinical Success Rate
93.3%

Based on 14 completed trials

Completion Rate
93%(14/15)
Active Trials
2(8%)
Results Posted
50%(7 trials)
Terminated
1(4%)

Phase Distribution

Ph not_applicable
2
8%
Ph phase_2
6
23%
Ph phase_1
4
15%
Ph phase_3
11
42%
Ph phase_4
3
12%

Phase Distribution

4

Early Stage

6

Mid Stage

14

Late Stage

Phase Distribution26 total trials
Phase 1Safety & dosage
4(15.4%)
Phase 2Efficacy & side effects
6(23.1%)
Phase 3Large-scale testing
11(42.3%)
Phase 4Post-market surveillance
3(11.5%)
N/ANon-phased studies
2(7.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.5%

14 of 16 finished

Non-Completion Rate

12.5%

2 ended early

Currently Active

2

trials recruiting

Total Trials

26

all time

Status Distribution
Active(3)
Completed(14)
Terminated(2)
Other(7)

Detailed Status

Completed14
unknown7
Recruiting2
Withdrawn1
Not yet recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
26
Active
2
Success Rate
93.3%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (15.4%)
Phase 26 (23.1%)
Phase 311 (42.3%)
Phase 43 (11.5%)
N/A2 (7.7%)

Trials by Status

withdrawn14%
completed1454%
recruiting28%
not_yet_recruiting14%
unknown727%
terminated14%

Recent Activity

Clinical Trials (26)

Showing 20 of 26 trialsScroll for more
NCT06799000Phase 3

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

Recruiting
NCT06840392Phase 3

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa

Recruiting
NCT07334054Not Applicable

Effect of Vitamin D and Branched-chain Amino Acids on Physical Performance and Biomarkers of Muscle Fatigue in Runners

Not Yet Recruiting
NCT06219915Phase 1

Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Placebo-Controlled Arm

Completed
NCT03193333Phase 3

PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM)

Terminated
NCT04376684Phase 2

Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease

Completed
NCT06183801Not Applicable

Effects of Probiotics on Metabolic Syndrome ,Intestinal Microflora and SCFA.

Completed
NCT02450773Phase 2

Prevention of Severe Postpartum Hypertension

Withdrawn
NCT05841394Phase 3

A Multi-center, Double-blinding, Parallel and Positive-controlled Phase III Clinical Trial for Efficacy and Safety Evaluation of Ilaprazole Sodium for Injection on Prevention of Stress Ulcer Bleeding

Completed
NCT04495283Phase 2

A Phase 2 Study to Evaluate Pregabalin and Acetaminophen Compared to Acetaminophen and Placebo in Subjects Undergoing Bunionectomy

Completed
NCT02803892Phase 2

Monotherapy With Rapamycin in Long-standing Type 1 Diabetes

Completed
NCT02839200Phase 2

Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder

Completed
NCT02827487Phase 4

Tramadol Versus Celecoxib in Reducing Pain Associated With IUD Insertion

Unknown
NCT00964782Phase 4

The Effects of Sildenafil on Exercise Function and Capacity in Patients With Fontan Circulation

Completed
NCT02555709Phase 1

An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers and Psoriatic Patients

Completed
NCT02766764Phase 4

Combined Dehydropeiandrosterone and Growth Hormone in Women With Expected Poor Ovarian Response Undergoing ICSI

Unknown
NCT01147848Phase 3

HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and Adolescents

Completed
NCT02104830Phase 3

Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Breast Cancer Patients

Completed
NCT02875639Phase 2

A Clinical Research of Qi Deficiency and Blood Stasis Syndrome (Different Disease With Syndrome)

Unknown
NCT02736019Phase 3

Tramadol Versus Celecoxib for Reducing Pain During Office Hysteroscopy in Post Menopausal Women

Unknown

Drug Details

Intervention Type
DRUG
Total Trials
26